Summary
Enrollment in companys first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached approximately 25% As recently announced,
Source: USA TODAY
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
